MX388831B - Metodos y composiciones para esteres anticolinergicos suaves. - Google Patents

Metodos y composiciones para esteres anticolinergicos suaves.

Info

Publication number
MX388831B
MX388831B MX2018003002A MX2018003002A MX388831B MX 388831 B MX388831 B MX 388831B MX 2018003002 A MX2018003002 A MX 2018003002A MX 2018003002 A MX2018003002 A MX 2018003002A MX 388831 B MX388831 B MX 388831B
Authority
MX
Mexico
Prior art keywords
compositions
methods
sialorrhea
intra
anticholinergic esters
Prior art date
Application number
MX2018003002A
Other languages
English (en)
Spanish (es)
Other versions
MX2018003002A (es
Inventor
Nicholas S Bodor
Original Assignee
Bodor Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bodor Laboratories Inc filed Critical Bodor Laboratories Inc
Publication of MX2018003002A publication Critical patent/MX2018003002A/es
Publication of MX388831B publication Critical patent/MX388831B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007Drug-containing films, membranes or sheets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018003002A 2015-09-11 2016-09-06 Metodos y composiciones para esteres anticolinergicos suaves. MX388831B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562217362P 2015-09-11 2015-09-11
PCT/US2016/050385 WO2017044412A1 (en) 2015-09-11 2016-09-06 Methods and compositions for soft anticholinergic esters

Publications (2)

Publication Number Publication Date
MX2018003002A MX2018003002A (es) 2018-08-01
MX388831B true MX388831B (es) 2025-03-20

Family

ID=58239861

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003002A MX388831B (es) 2015-09-11 2016-09-06 Metodos y composiciones para esteres anticolinergicos suaves.

Country Status (12)

Country Link
US (4) US11534422B2 (https=)
EP (1) EP3347007B1 (https=)
JP (4) JP7270958B2 (https=)
KR (1) KR102889909B1 (https=)
CN (4) CN118021770A (https=)
AU (2) AU2016318595B2 (https=)
ES (1) ES2942361T3 (https=)
IL (1) IL257970B (https=)
MX (1) MX388831B (https=)
MY (1) MY197265A (https=)
WO (1) WO2017044412A1 (https=)
ZA (1) ZA201801685B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109044965A (zh) * 2018-10-17 2018-12-21 广州大光制药有限公司 格隆溴铵的眼用药物组合物及医药用途
CA3174550A1 (en) * 2020-03-03 2021-09-10 Kaken Pharmaceutical Co., Ltd. Medicament containing sofpironium bromide
KR20240088983A (ko) 2021-11-01 2024-06-20 유타대학연구재단 침흘림증 치료를 위한 조성물 및 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
WO2001008681A1 (en) 1999-08-02 2001-02-08 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
US9198897B2 (en) 2005-01-19 2015-12-01 Neurohealing Pharmaceuticals, Inc. Methods and compositions for decreasing saliva production
US7417147B2 (en) 2005-11-10 2008-08-26 Bodor Nicholas S Soft anticholinergic zwitterions
ATE529399T1 (de) 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
US8071693B2 (en) 2006-06-22 2011-12-06 Sabic Innovative Plastics Ip B.V. Polysiloxane/polyimide copolymers and blends thereof
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
AU2008268465A1 (en) 2007-06-22 2008-12-31 Sciele Pharma, Inc. Transdermal delivery system comprising glycopyrrolate to treat sialorrhea
CN102016595B (zh) 2008-03-27 2014-08-06 哈佛学院院长等 三维微流体装置
KR102241660B1 (ko) 2013-03-15 2021-04-19 보도르 라보래토리즈, 인크. 다한증 치료용 항콜린성 글리코피롤레이트 에스테르

Also Published As

Publication number Publication date
US20260108491A1 (en) 2026-04-23
IL257970A (en) 2018-05-31
US11534422B2 (en) 2022-12-27
CN118021770A (zh) 2024-05-14
JP2018526420A (ja) 2018-09-13
EP3347007B1 (en) 2023-03-29
KR20180061220A (ko) 2018-06-07
US12458625B2 (en) 2025-11-04
JP2023164671A (ja) 2023-11-10
IL257970B (en) 2021-04-29
JP2021001238A (ja) 2021-01-07
MY197265A (en) 2023-06-08
KR102889909B1 (ko) 2025-11-24
JP7270958B2 (ja) 2023-05-11
CN118021797A (zh) 2024-05-14
CA2998357A1 (en) 2017-03-16
US20180250265A1 (en) 2018-09-06
ZA201801685B (en) 2023-12-20
EP3347007A4 (en) 2019-05-08
CN118045082A (zh) 2024-05-17
MX2018003002A (es) 2018-08-01
AU2021204306A1 (en) 2021-07-22
JP7723417B2 (ja) 2025-08-14
CN108348502A (zh) 2018-07-31
EP3347007A1 (en) 2018-07-18
AU2016318595B2 (en) 2021-07-08
US20220401410A1 (en) 2022-12-22
ES2942361T3 (es) 2023-05-31
AU2021204306B2 (en) 2023-11-09
US20240261262A1 (en) 2024-08-08
US11951093B2 (en) 2024-04-09
AU2016318595A1 (en) 2018-04-26
WO2017044412A1 (en) 2017-03-16
JP2022132446A (ja) 2022-09-08
HK1255558A1 (en) 2019-08-23

Similar Documents

Publication Publication Date Title
JOP20200011B1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
PH12016501732A1 (en) Formulation for soft anticholinergic analogs
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
MX2018000918A (es) Formulacion para analogos anticolinergicos blandos.
EP3386484A4 (en) COMPOSITIONS AND METHODS OF DELIVERING THERAPEUTIC ACTIVITIES
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
PH12019500142A1 (en) Formulation for soft anticholinergic analogs
BR112017000024A2 (pt) composição para tratamento de tecidos que compreende uma nanoemulsão polimérica de aminossiloxano
MX2019006893A (es) Inhibidores heterociclicos de mct4.
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
WO2017019540A3 (en) Inhibitors of n-linked glycosylation and methods using same
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
UA120999C2 (uk) Естери оксаборолу та їх використання
MX373714B (es) Composiciones de ketoprofeno de accion prolongada.
ZA201801685B (en) Methods and compositions for soft anticholinergic esters
BR112015016391A2 (pt) carboxamidas i baseadas em pirazolil como inibidoras do canal crac
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
EA201692493A1 (ru) Противомикробные фармацевтические композиции со способностями ингибирования множественной лекарственной устойчивости
BR112015016394A2 (pt) carboxamidas ii baseadas em pirazolil como inibidoras do canal crac
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
EA201792685A1 (ru) Фармацевтическая композиция для лечения воспалительных изменений прямой кишки
HUE043237T2 (hu) Propoliszt és karnozinsavat tartalmazó szinergikus készítmény kandidiázis megelõzésében és kezelésében történõ alkalmazásra
IL280569A (en) Methods and compositions for the treatment of ultraviolet radiation damage b